Torrent Pharmaceuticals has successfully concluded a USFDA inspection of its Bileshwarpura oncology facility. The site audit, conducted between April 6, 2026, and April 10, 2026, resulted in a clean report with zero observations. This positive outcome underscores the company’s commitment to maintaining high-quality manufacturing standards across its specialized pharmaceutical operations.
Successful USFDA Inspection
Torrent Pharmaceuticals announced that its oncology manufacturing facility located in Bileshwarpura has undergone a routine inspection by the United States Food and Drug Administration (USFDA). The audit took place from April 6, 2026, to April 10, 2026, as part of the agency’s ongoing oversight of international pharmaceutical manufacturing sites.
Clean Audit Results
The company confirmed that the inspection concluded successfully with zero observations. Receiving a clean report—an ‘Establishment Inspection Report’ (EIR) without any Form 483 citations—reflects the robustness of the quality control and operational systems in place at the Bileshwarpura site. This development ensures continued compliance and operational readiness for the company’s oncology portfolio in regulated markets.
Source: BSE
